

**ASSOCIATION FOR MULTIPLE ENDOCRINE
NEOPLASIA DISORDERS (AMEND)**

FINANCIAL STATEMENTS

YEAR ENDED 31st DECEMBER 2024

CHARITY NUMBER: 1153890

CONTENTS

<u>REPORT OF THE TRUSTEES</u>	3
ORGANISATIONAL STRUCTURE AND DECISION MAKING	3
THE CHARITY'S AIMS AND OBJECTIVES	4
PUBLIC BENEFIT	4
ACTIVITIES AND ACHIEVEMENTS	5
FINANCIAL REVIEW	9
FINANCIAL RESERVES POLICY	9
RISK MANAGEMENT	10
GOING FORWARD	10
TRUSTEE'S RESPONSIBILITIES IN RELATION TO THE FINANCIAL STATEMENTS	11
CHAIRPERSON'S REPORT	11
CHIEF EXECUTIVE'S REPORT	12
<u>REFERENCE AND ADMINISTRATIVE DETAILS</u>	13
<u>STATEMENT OF FINANCIAL ACTIVITIES</u>	15
<u>BALANCE SHEET</u>	16
<u>NOTES TO THE FINANCIAL STATEMENTS</u>	18

ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS (AMEND)

YEAR ENDING 31st DECEMBER 2024

REPORT OF THE TRUSTEES

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 March 2024. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

AMEND is a Charitable Incorporated Organisation (no.1153890), governed by a constitution, vesting control, and responsibility in the Trustee Board on behalf of the membership.

AMEND has been registered with the Charity Commission as a CIO since September 20th, 2013, and previously an unincorporated association (no. 1099796) from October 2003. The charity's current Constitution was amended on May 7th, 2016. This amendment was approved by the Charity Commission.

Organisational Structure and Decision Making

The Charity is governed by its Trustees, who are appointed by the Charity membership. Trustees are appointed for a period of three years after which they may seek re-election. The constitution states that there must no less than 3 and no more than 12 Trustees. A process of Trustee elections takes place most years in order to maintain an adequate number of Trustees and to allow for the replacement of those who have completed their term of service. A Chairperson for the Trustees is appointed by the Trustees.

Persons nominated to become Trustees of the Charity must be a member of the Charity and remain a member of the Charity during their tenure.

Trustees are responsible for the strategic direction and operational management of the Charity. When appropriate and necessary the specialist expertise of members and friends is sought to assist in decision-making e.g. in relation to matters of finance, safeguarding and Charity fabric issues.

All elected Trustees will have access to relevant documentation from the Charity Commission pertaining to their responsibilities as a charity trustee, the Charity's policies, and appropriate guidance materials. Pay reviews for staff are conducted annually by the Trustees.

The policies adopted are those of the Charity Commission publications as per the website. Trustees are reminded periodically to review these documents, and new trustees are issued with access to copies for pursual.

ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS (AMEND)
YEAR ENDING 31st DECEMBER 2024

The Charity's Aims and Objectives

The object of the Charitable Incorporated Organisation (CIO) is to relieve people who suffer from Multiple Endocrine Neoplasia (M.E.N.) of all types, their families, friends, and carers by all or any of the following means:

1. Acting as a reliable and accurate source of information for the public concerning M.E.N. and its associated sporadic growths, by:
 - a. Working with the approval of members of the medical profession who are directly involved in the treatment and research into M.E.N.
 - b. Collecting, collating, and distributing appropriate and approved information.
 - c. Producing the Charity's own patient-aimed approved information.
2. Promoting a wider knowledge of the illnesses among the medical profession to assist in early and accurate diagnosis.
3. Providing reliable and accurate information with regard to genetic testing for people with M.E.N. and its associated familial growths, their families, friends, and carers.
4. Providing emotional support to patients, their families, friends, and carers in the form of contact with others in similar situations in order to facilitate the sharing of experiences.

Public Benefit

The Trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities should be undertaken by the Charity.

AMEND is dedicated to supporting individuals affected by multiple endocrine neoplasia (MEN) and related endocrine disorders. Our mission is to provide comprehensive support, information, and advocacy to improve the lives of those affected.

Our primary beneficiaries are individuals and families affected by MEN and related endocrine disorders. We support them through direct services, educational materials, and support and advocacy efforts.

AMEND's activities are designed to provide clear public benefit, in line with the Charity Commission's requirements. We regularly review our policies to ensure compliance and effectiveness.

ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS (AMEND)

YEAR ENDING 31st DECEMBER 2024

Activities and Achievements

Source of Information

In 2024 we started a new project to develop webcasts on different topics. We began with a webcast with AMEND Trustee and Medical Advisor, Professor Karim Meeran (London) on corticosteroids, a class of prescription medication used by many within our communities. This helped to explore some of the myths around steroid treatment. In our second webcast for 2024, we chatted with one of our fundraisers, Steph Webb, who had recently taken up running, and had decided to run 8 different fundraising events in aid of AMEND. The webcast project is continuing into 2025.

AMEND's 2024 Annual Patient Information Day was held on Saturday 1st June in central Birmingham. Almost 100 people attended, including 8 speakers. 38 people completed our feedback survey, reporting that for more than 60%, this had been their first experience of an AMEND Patient Information Day. The majority of sessions attended were rated as excellent, in particular the 2-hour disease-specific Q&A sessions.

'Excellent, well-organised and informative. Gives me confidence we are supported.'

We developed A4 tear-off pads containing QR codes for accessing, downloading, and printing all our MEN-related patient information books. These will be for use in clinics to give to patients when they are diagnosed and/or facing treatment. This will avoid the current expense of giving out large quantities of our designed and printed books to hospitals.

On social media, we moved our three accounts (AMEND, ACC Support UK, Phaeo Para Support UK) to BlueSky under a single AMEND account to help increase brand recognition and reach in a less toxic environment.

In late 2024, we began preparations for the redevelopment of the ACC Support UK website, thanks to legacy funding from the family and friends of the late Sally Zelenczuk. This work is expected to complete in Spring 2025.

ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS (AMEND)

YEAR ENDING 31st DECEMBER 2024

Provision of Support

Our 4 wonderful Peer Support Volunteers held 12 Peer Support Meetings throughout the year, supporting approximately 30 people in total. In addition, our Scottish Peer Support Volunteer held a Peer Support and Information event in Scotland featuring a Genetic Counsellor speaker, supporting 6 people. We also trialled meetings for partners or carers which was successful, and which now forms part of our ongoing meetings provision. Our Volunteers also took part in their virtual annual training session in the Autumn. Part-way through the year, we successfully recruited a new Peer Support Volunteer, but another sadly stepped down. We continue to recruit new volunteers on an ongoing basis.

AMEND's psychological support provider, Rareminds, provided 211 one-to-one counselling sessions to a total of 30 members (mean average number of sessions per person x7) at a cost of £13,155. Feedback from 20 users of the service who responded to their end-of-treatment survey was very positive:

- 14 out of 20 (70%) felt that the counselling had been 'very helpful'; 2 clients found it 'helpful'; 4 clients found it 'quite helpful'
- 18 out of 20 (90%) felt that it was very helpful and important to have a counsellor who understood the impact of the condition, 1 client thought it was quite helpful and important., 1 client did not think it was important.
- 19 out of 20 (99.5%) felt better equipped to manage the emotional impact of their condition following their sessions
- 20 out of 20 (100%) would recommend their counsellor to others

"My counsellor was hugely supportive, friendly, and helpful. I felt they had a great understanding of the issues affecting me and understood the complexity of dealing with long term chronic conditions which are very stressful. I would recommend them to anyone as I thought they were brilliant."

Advocacy & Raising Awareness

Throughout the year, AMEND CEO, Jo Grey, was honoured to be asked to talk about AMEND and patients' perspectives of unmet needs in their care at the following:

- UK & Ireland Neuroendocrine Tumours Society (UKINETS)
- University of Birmingham SIMBA 3.0 Adrenal meeting
- Seoul International Congress on Endocrinology & Metabolism (SICEM), South Korea
- Webinar for the European Reference Network for Rare Endocrine Conditions (ENDO ERN) with Professor Frederic Castinetti (Marseille)
- Society for Endocrinology Clinical Update Meeting

In August, Genomics England removed the *RET* gene (that causes MEN2/3) from their new-born screening research study. AMEND submitted a response expressing disappointment at this decision. We are grateful to Clinical Geneticists, Drs Fiona Laloo and Louise Izatt, for working with the research team on this, which has resulted in *RET* mutation in codon 918 (MEN2B) being reinstated into the study at the next phase.

ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS (AMEND)
YEAR ENDING 31st DECEMBER 2024

We were honoured to be invited by surgeon, Mr Tom Kurzawinski, to co-write an article for the journal, Endocrine-Related Cancer, about patient experiences of living with a RET gene mutation (causing MEN2 and MEN3). Called 'Living with a RET gene mutation: Patients' Perspectives,' the article, co-authored with retired Great Ormond Street Hospital Paediatric Endocrinologist, Dr Caroline Brain, explores the experiences of 4 families through diagnosis and treatment. We highlighted the need for earlier diagnosis, improved psychological support at diagnosis, the importance of wider family predictive genetic testing, and the need for families to be cared for in centres of expertise. We thank all the families involved for their input.

AMEND and Neuroendocrine Cancer UK (NCUK) began negotiations for forming an alliance, called the Neuroendocrine Life Alliance. The Alliance's mission is to align the charities' strategic priorities to raise awareness, educate, support, and advocate for all our neuroendocrine disease communities. The Alliance's aims are to:

1. Share knowledge and resources for the good of neuroendocrine communities
2. Develop joint key strategic projects, including:
 - a. Education programmes
 - b. Support and wellbeing initiatives
 - c. Awareness-raising activities
 - d. Advocacy and policy work

The Neuroendocrine Life Alliance is a work in progress, with 2025 agreed for its launch.

Encouraging Research

Thanks to the Elliot Dallen Trust, we were able to support another £10,000 award for research into adrenocortical cancer (ACC). This was the last year in a 3-year financial commitment to funding research projects through AMEND. The 2024 ACC Research Grant was awarded to Dr Cristina Ronchi from the University of Birmingham for her continuing work to develop a less invasive way to manage ACC patients using blood tests, and minimising use of imaging (Circulating cell-free DNA-based biomarkers for longitudinal monitoring of patients with adrenocortical carcinoma).

As a member of the European MEN Alliance, we distributed their survey on Unmet Needs in MEN Syndromes to our multiple endocrine neoplasia community. This survey is ongoing into 2025. We look forward to being able to use the data gained to raise awareness of issues patients perceive in the care and management of their disease.

We distributed a preliminary research survey by Dr Ruth Casey from the University of Cambridge on pregnancy and starting a family to our multiple endocrine neoplasia community.

ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS (AMEND)
YEAR ENDING 31st DECEMBER 2024

Fundraising

We send our thanks to all our 2024 fundraisers who took on a range of challenges for sponsorship in aid of AMEND:

- Steph Webb – x8 fundraising runs
- Ella Stevens – Skydive
- Jess and Carl – Three Peaks Challenge
- Steph, Sam, Rick - Saucony London 10k
- Jack Greasley - UWCB Boxing event
- Ryan Keeshan - London Marathon
- Drew and Laura - Norfolk coastline walk (84 miles)
- Emma William's - cycling challenge
- Deborah O'Riordan - Brighton Marathon
- Evie Pearce – swimming challenge
- Nick, Lucy, Scott, Ben & Dom - Bristol 10k run
- Deborah O'Riordan – Brighton 10k run
- Tom and Laura Mann – Norwich 10k run
- Barnes Construction Not Fayers Golf Day

Thanks also to all those who donate on a regular basis, who purchase merchandise from our websites and TeeShop, and who continue to use the free fundraising platforms for online purchases. All income from these methods go to support our work.

ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS (AMEND)

YEAR ENDING 31st DECEMBER 2024

Financial Review

The charity's total incoming resources were £95,173 (2023: £80,668). Given the pressure from the cost-of-living crisis and reduced public spending, AMEND has performed well. There was a significant increase in donations and legacies, indicating successful fundraising efforts and increased donor engagement. This mitigated the decrease in income from charitable activities, where AMEND saw a decrease in demand for events/activities generating revenue compared to the previous year. Investment income increased significantly, reflecting better returns on investments, possibly due to favourable market conditions or improved investment strategies. Other income reduced slightly due to lower merchandise sales, which tends to fluctuate each year.

Total expenditure for the year was £106,016 (2023: £112,292). Despite the increase in income, the charity ended the year with a deficit of £10,843, compared to a deficit of £31,624 in 2023. This is a fantastic result for AMEND as it brings us closer to breaking even and limits the reduction in free reserves.

The increase in expenditure on raising funds suggests more investment in fundraising activities, which may have contributed to the higher income from donations and legacies. Expenditure on charitable activities decreased due to more efficient use of resources and fewer activities conducted during the year. Support costs slightly decreased due to better management of administrative expenses. Overall net expenditure decreased significantly, reflecting better financial management and increased efficiency in operations.

We managed to fund £13,240 towards our valuable counselling service and made research grants and awards totalling £10,000 during the year. We would like to thank our members and grant funders who continue to support us.

AMEND's undesignated unrestricted reserves stand at £76,915 (2023: £38,234). The reclassification of certain funds to unrestricted status in 2024 provides greater flexibility in the allocation and utilisation of resources, especially due to the high-risk nature of the main funding stream (donations and voluntary grants).

Financial Reserves Policy

In 2024, the Trustees reviewed and amended the Financial Reserves policy to state that they considered it prudent to hold a reserve of at least £60,000 (with £10,000 permanently maintained on demand) to ensure that AMEND's core activities could continue for a period of 6 months in the event of unforeseen difficulties. At the year-end, although the bank balance in the various Current Accounts was £28,393, the Trustees consider the position to be satisfactory as there was a further £84,870 held on the Flagstone account; a total of £113,263.

The trustees review this policy every 6 months at Board Meetings.

ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS (AMEND)

YEAR ENDING 31st DECEMBER 2024

Risk Management

The Trustees have a duty to identify and review the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error. Having assessed the risks, the Trustees are satisfied that systems are in place to mitigate exposure to the major ones. Internal control risks are minimised by the implementation of procedures for all transactions and projects. Procedures are also in place to ensure compliance with the health and safety of members, their families, friends, and carers.

For example, two factor authentication is used on all CMS and finance software systems, two signatories are required for financial transactions, and up-to-date internet security services are in place on all IT devices. Trustee and public liability insurance is in place and renewed regularly, along with insurance for the AMEND office.

Going Forward

The 'buzzword' for AMEND's future is 'sustainability.' This work looks at finding more future-proofed and efficient ways to continue to provide all the services we do now into the next few years. Not just this but also ensuring that personnel sustainability is considered through succession planning, and through recruiting volunteers to assist with various aspects of AMEND's work, such as our social media awareness work. Financial sustainability of course is the thread that runs through all of our work; the need to ensure that AMEND does not rely on one main source of income, but rather, that we work towards a more diverse set of income streams. As ever, the fundraising of our members and friends are critical to the future of AMEND.

Specific projects for 2025 include the development and launch of the new ACC Support UK website, including the development of patient information for parents of children with ACC.

We will continue our AMEND Webcast project as an efficient and effective information resource for our communities on a range of topics of interest. Already in 2025, we have launched Webcasts on Medical Guidelines, and on Parathyroid Surgery.

We continue our work with our patient group colleagues, including within Europe and the wider international community, to create a louder voice to increase awareness of and research interest in our diseases.

As always, we will continue to work with our Medical Advisory Teams to update our patient information resources, and with our support colleagues at Rareminds, and with our Peer Support Volunteers, to ensure that no one is left to deal with their disease alone.

ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS (AMEND)

YEAR ENDING 31st DECEMBER 2024

Trustee's Responsibilities in Relation to the Financial Statements

The Trustees are responsible for preparing the Trustee's Annual Report and the financial statements in accordance with the Charities Act 2011 and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England and Wales requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Charity and of the incoming resources and application of resources of the charity for that period. The trustees are responsible for keeping proper accounting records and ensuring compliance with the Charities Act 2011, the Charity Regulations 2008, and the provisions of the trust deed.

They are specifically required to:

- Select suitable accounting policies and then apply them consistently.
- Observe the methods and principles of the Charities SORP.
- Make judgements and estimates that are reasonable and prudent.
- State whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements.
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that charity will continue in operation.

Approved by order of the Board of Trustees on Monday 21 July 2025 and signed on their behalf by:



Gill Masters (Chair)



Lauren Wheeler (Treasurer)

Chairperson's Report

Reflecting on AMEND's sustainability, we are pleased to see that various efforts to increase income and reduce expenditure during 2024 have resulted in a much-improved financial performance in a difficult climate. Grant funding remains hard to come by so the contribution to the charity's income made by our wonderful fundraisers is very important. We are grateful to everyone internally, board members and to our patients and supporters for their ongoing hard work.

We continue to concentrate on educating and supporting patients and their families, raising awareness of the conditions we support amongst medical professionals and providing accurate and up to date information for everyone who needs it. We can only do this with your support – thank you, it is very much appreciated!

ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS (AMEND)

YEAR ENDING 31st DECEMBER 2024

Chief Executive's Report

At a time when costs are increasing, we are very grateful to everyone who donated, fundraised, or gave AMEND grants or in-kind help in 2024. Accessing grants however remains challenging, with so many other worthy charities applying too. We took a good look at ways to be more efficient and effective, and made a variety of changes to reduce expenditure. As you will have read, we continued our other charitable activities throughout the year with little to no impact from our cost-cutting measures. We could not do what we do without the wonderful help of all our volunteers, including our Peer Support Volunteers, Trustees, Medical Advisory Teams, and anyone who has helped the charity in any way during the year. It truly is a patient group run by patients, just as it was intended to be.

ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS (AMEND)

YEAR ENDING 31st DECEMBER 2024

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Charity Number: 1153890

Principal Office: AMEND, Tyler House, 58-66 Morley Road, Tonbridge, Kent, TN9 1RA

Bank: Charities Aid Foundation Bank, 25 Kings Hill Avenue, Kings Hill, West Malling, Kent ME19 4JQ

Trustees as at December 31 2024

Gill Masters (Chair)

Lauren Wheeler (Incoming Treasurer) – Elected onto Board 15th August 2024

Catherine Hamilton-Woodthorpe (Outgoing Treasurer) (Resigned 15/08/2024)

Shahab Khan

Sarah Norman

Graeme Cohen

Mr Robert Millinship

Andy Price

Dr John Ayuk

Ms Miriam Asia, RN

Professor Karim Meeran

Karen Williams (Resigned 15/08/2024)

Patrons

Recorder, Mrs Jo Delahunty, KC, MA (Oxon) Jurisprudence

Professor Rajesh Thakker, May Professor of Medicine, OCDEM, Churchill Hospital, Oxford

Mr Shaun Williamson, Actor

Independent Examiner

Dynamix Accountancy: Dane John Works, Gordon Road, Canterbury, Kent, CT1 3PP

ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS (AMEND)

YEAR ENDING 31st DECEMBER 2024

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF

ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS (AMEND)

Independent examiner's report to the trustees of ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS (AMEND)

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2024.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Hussein Bhaiji

Hussein Bhaiji (FCCA)
Association of Chartered Certified Accountants
Dynamix Accountancy
Dane John Works
Gordon Road, Canterbury
Kent, CT1 3PP

Date: 21st July 2025

ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS (AMEND)

YEAR ENDING 31st DECEMBER 2024

STATEMENT OF FINANCIAL ACTIVITIES

	Note	Unrestricted	Restricted	TOTAL	2023
		£	£	£	£
Income					
Donations and Legacies	2.	50,648	8,646	59,294	36,788
Charitable Activities	3.	20,000	10,000	30,000	41,369
Investment Income	4.	5,451	-	5,451	1,977
Other Income	5.	428	-	428	534
Total Income		76,527	18,646	95,173	80,668
Expenditure					
Raising funds	6.	14,791	-	14,791	9,635
Charitable Activities	7.	51,211	20,756	71,966	81,789
Support Costs	8.	17,319	107	17,426	17,967
Governance Costs	9.	1,832	-	1,832	2,901
Total Expenditure		85,153	20,863	106,016	112,292
Net Income /(expenditure) for the year		(8,627)	(2,217)	(10,843)	(31,624)
Transfers between funds	17.	7,539	- 7,539	-	-
Net Movement in Funds		(1,088)	(9,756)	(10,843)	(31,624)
Reconciliation of Funds					
Total Funds brought forward		108,003	17,033	125,036	156,660
Total Charity Funds carried forward		106,915	7,277	114,193	125,036

Comparative figures for 2023 are in Note 22.

All incoming resources and resources expended derive from continuing activities

The Notes on pages 18-28 form part of the Financial Statements

ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS (AMEND)

YEAR ENDING 31st DECEMBER 2024

BALANCE SHEET

	Note	2024		2023	
		£	£	£	£
Fixed Assets					
Tangible Fixed Assets	11.		583		1,039
			583		1,039
Current Assets					
Stocks		2,496		3,166	
Debtors & Prepayments	12.	5,646		7,170	
Cash and Bank in Hand	13.	<u>113,263</u>		<u>115,729</u>	
		121,404		126,065	
Current Liabilities due within one year					
Creditors	14.	<u>(7,794)</u>		<u>(2,068)</u>	
		(7,794)		(2,068)	
Net Current Assets			113,611		123,997
Total Net Assets			<u>114,193</u>		<u>125,036</u>
Charity Funds					
Restricted funds	16.		7,277		17,033
Unrestricted funds:	17.	76,915		38,234	
Designated funds	18.	<u>30,000</u>		<u>69,769</u>	
			106,915		108,003
Total Charity Funds carried forward			<u>114,193</u>		<u>125,036</u>

The charitable company is entitled to exemption from audit under section 477 of the Companies Act 2006 for the year ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for:

(a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and

(b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS (AMEND)
YEAR ENDING 31st DECEMBER 2024

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies' regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 21st July 2025 and were signed on its behalf by:



Gill Masters (Chair)



Lauren Wheeler (Treasurer)

ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS (AMEND)

YEAR ENDING 31st DECEMBER 2024

NOTES TO THE FINANCIAL STATEMENTS

1. Accounting Policies

1.1 Charity Information

Association for Multiple Endocrine Neoplasia Disorders (AMEND) is an incorporated charity whose registered address is Tyler House, 58-66 Morley Road, Tonbridge, Kent, TN9 1RA.

1.2 Basis of Preparation

The Financial Statements have been prepared in accordance with the Charity's governing document, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)".

The Financial Statements have been prepared under the historical cost convention.

The Charity constitutes a Public Benefit Entity as defined by FRS 102.

1.3 Going Concern

The Trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern.

1.4 Critical Accounting Estimates and Judgements

The preparation of the Financial Statements requires the Trustees to make judgements, estimates and assumptions that affect the amounts reported for assets and liabilities as at the Balance Sheet date and the amounts reported for revenues and expenses during the year. The estimates and associated assumptions are based on historical experience and other relevant factors. However, the nature of estimation means that actual outcomes could be different.

1.5 Income Recognition

Income is recognised in the Statement of Financial Activities on the following basis:

- (a) Donations are recognised when the Charity has been notified in writing of both the amount and settlement date. In the event that a donation is subject to conditions that require a level of performance before the Charity is entitled to the funds, the income is deferred and not recognised until either those conditions are fully met, or the fulfilment of those conditions is wholly within the control of the Charity and it is probable that those conditions will be fulfilled in the reporting period.
- (b) Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity, normally on notification by the bank.
- (c) Income Tax recoverable on donations under Gift Aid is recognised in the period of which the original donation relates to.
- (d) Grant income is recognised when there is reasonable assurance that the grant will be received, and that the charity will comply with the conditions attached to the grant.
Grants received for specific purposes shall be recognised as income in the period in which the related expenses are incurred. Unrestricted grants shall be recognised as income when received or receivable. Grants received in advance of the related expenditure shall be recognised as deferred income and released to income as the related expenditure is incurred.
- (e) Income from the sale of merchandise is recognised when the significant risks and rewards of ownership have been transferred to the buyer. Income is recognised net of any discounts, returns, and allowances.

ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS (AMEND)

YEAR ENDING 31st DECEMBER 2024

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

1. Accounting Policies (continued)

1.6 Expenditure Recognition

- (a) Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the Charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.
- (b) Expenditure is accounted for on an accrual's basis.
- (c) Expenditure is allocated by activity in the first instance and, where practical, is also allocated to a cost centre.

1.7 Tangible Fixed Assets

All assets costing more than £1,000 are capitalised.

Impairment of assets

At each reporting end date, the Charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

Depreciation

Computer equipment is depreciated over 3 years.
Office furniture depreciated over 5 years.

1.8 Stocks

Stocks of unsold merchandise in the Charity are valued at the lower of cost and net realisable value.

1.9 Taxation

As AMEND is a Charitable Incorporated Organisation, the Charity is not liable to income or capital taxes.

1.10 Fund accounting

Unrestricted "General" funds can be used in accordance with the charitable objectives at the discretion of the Trustees.

Designated funds are unrestricted funds earmarked for a specific project or aim: they can be returned to the General unrestricted funds at any time at the discretion of the Trustees. For reporting purposes, they are combined with unrestricted funds and termed "Unrestricted".

Restricted funds can only be used for particular restricted purposes within the objects of the Charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes, and where the funder may require repayment if the conditions are not met.

Further explanation of the nature and purpose of each fund is included in the Notes to the Financial Statements.

1.11 Pension costs and other post-retirement benefits

The Charity operates Defined Contribution plans for its employees. Once the agreed contributions have been paid the Charity has no further payment obligations. The contributions are recognised as an expense when they are due: amounts not paid at the year-end are shown in creditors in the Balance Sheet.

ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS (AMEND)

YEAR ENDING 31st DECEMBER 2024

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

	Unrestricted	Restricted	TOTAL	2023
	£	£	£	£
2. Donations and Legacies				
Donations and Gift Aid	50,648	8,646	59,294	36,788
	-	-	-	-
Total	50,648	8,646	59,294	36,788
3. Charitable Activities	£	£	£	£
Grants	20,000	10,000	30,000	41,369
	-	-	-	-
Total	20,000	10,000	30,000	41,369
4. Investment Income	£	£	£	£
Bank interest	5,451	-	5,451	1,977
Total	5,451	-	5,451	1,977
5. Other Income	£	£	£	£
Sale of Merchandise	426	-	426	523
Other income	2	-	2	11
Total	428	-	428	534
6. Raising funds	£	£	£	£
Staff costs	9,980	-	9,980	7,239
Merchandise	870	-	870	811
Other	3,941	-	3,941	1,585
	14,791	-	14,791	9,635

ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS (AMEND)

YEAR ENDING 31st DECEMBER 2024

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

	Unrestricted	Restricted	TOTAL	2023
	£	£	£	£
7. Charitable Activities				
Staff costs	24,092	-	24,092	24,365
Patient information printing, booklets, and websites	3,403	-	3,403	6,352
Patient information events and conferences	1,982	9,875	11,857	8,073
Patient education films	-	-	-	-
Patient representation	209	-	209	98
Research grants and awards	-	10,000	10,000	15,500
ACC support and ACC research grants	384	-	384	402
ACC staff costs	-	-	-	9,048
Patient support and counselling	13,857	881	14,738	17,567
PPS UK	384	-	384	384
Total	51,211	20,756	71,966	81,789
8. Support Costs				
Rent	9,360	-	9,360	9,360
Staff costs	4,316	-	4,316	4,589
Printing, postage, and office supplies	996	-	996	661
Telephone	504	-	504	462
IT support	23	-	23	18
IT software and consumables	783	-	783	897
Insurance	508	-	508	625
Finance charges	91	-	91	157
Exchange difference	-	-	-	44
Legal fees	-	-	-	35
Repairs and maintenance	-	-	-	63
Subscriptions	203	-	203	117
General	79	107	187	-
Depreciation	457	-	457	939
Total	17,319	107	17,426	17,967

ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS (AMEND)

YEAR ENDING 31st DECEMBER 2024

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

	Unrestricted	Restricted	TOTAL	2023
	£	£	£	£
9. Governance Costs				
Audit / Independent Examination	960	-	960	2,400
Other governance costs	872	-	872	501
Total	1,832	-	1,832	2,901

10. Staff Numbers

The average number of employees during the year was 2 (2023: 2).

11. Tangible Fixed Assets

	Computer Equipment	Office Equipment	Total Tangible Fixed Assets
	£	£	£
Cost or valuation			
At 1st January 2024	3,448	10,673	14,121
Additions	-	-	-
Disposals	-	-	-
At 31st December 2024	3,448	10,673	14,121

Depreciation

At 1st January 2024	3,231	9,850	13,082
Charge	217	240	457
At 31st December 2024	3,448	10,090	13,538

Net Book Value

At 31st December 2024	-	583	583
At 31st December 2023	217	823	1,039

ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS (AMEND)

YEAR ENDING 31st DECEMBER 2024

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

12. Debtors & Prepayments: amounts falling due within one year:

	Unrestricted	Restricted	TOTAL	2023
	£	£	£	£
Trade debtors	-	-	-	-
Prepayments and accrued income	5,646	-	5,646	7,170
	5,646	-	5,646	7,170

13. Cash and Bank in Hand

	£	£	£	£
Current Accounts	28,393	-	28,393	34,947
Deposit Reserve Accounts	84,870	-	84,870	80,782
	113,263	-	113,263	115,729

14. Creditors: amounts falling due within one year:

	£	£	£	£
Other taxation and social security	1,425	-	1,425	195
Other creditors	4,257	-	4,257	248
Trade creditors and accruals	2,112	-	2,112	1,625
	7,794	-	7,794	2,068

15. Deferred Income

	2024	2023
	£	£
Arising from grants, memberships, events, and training	4,000	-

Deferred income is included in the financial statements as follows:

	2024	2023
	£	£
Deferred income is included within:		
Current Liabilities	<u>4,000</u>	<u>-</u>
Movements in the year:		
Brought forward	-	-
Released from previous periods	-	-
Resources deferred in the year	4,000	-
	<u>-</u>	<u>-</u>
Deferred income at 31 December 2024	<u>4,000</u>	<u>-</u>

ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS (AMEND)

YEAR ENDING 31st DECEMBER 2024

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

16. Restricted Funds

	01/01/2024	Income	Expenditure	Transfer	31/12/2024
	£	£	£	£	£
Barnes Construction Golf Day	7,079	-	-	(7,079)	-
HRA Pharma - ACC films	5,000	6,000	(7,228)	-	3,772
Licence to use ACC film clips	800	-	-	(800)	-
Society for Endocrinology	-	-	-	-	-
Project Rollercoaster	-	-	(340)	340	-
National Lottery Community Fund - peer support	4,154	-	(648)	-	3,506
Elliot Dallan Charitable Trust	-	10,000	(10,000)	-	-
Korean Endocrine Society		2,646	(2,646)		-
	17,033	18,646	(20,863)	(7,539)	7,277

Restricted Funds

Barnes Construction Golf Day	The proceeds from Barnes Construction's Golf Day will be allocated to MEN1 research awards. In subsequent years, Barnes Construction's donations have been unrestricted, with the terms for this funding now released. As a result, this fund has been moved to unrestricted funds starting in 2024.
HRA Pharma - AIPD	HRA Pharma provided a grant in 2019 and 2024 to meet the costs of the annual Patient Information Day.
Licence to use ACC film clips	Licence given to HRA Pharma for use of ACC patient film clips and to be used against future ACC podcasts. Given that the terms of this funding are no longer subject to restrictions, the fund has been reclassified as unrestricted from 2024. This change reflects the updated status of the funding terms, allowing for greater flexibility in the allocation and utilisation of these resources.
Society for Endocrinology	Society for Endocrinology Patient Grant to update resources
Big Give - Counselling	Big Give Christmas Challenge Campaign raised funds for our Counselling Service
National Lottery Community Fund - peer support	The National Lottery Community Fund provided a grant for our Peer Support Meetings for 2022-23
Elliot Dallan Charitable Trust	The Elliot Dallan Charitable Trust provided a grant of £10,000 for a research grant into adrenocortical cancer.
Korean Endocrine Society	The Korean Endocrine Society donated £2,646 to the charity in order to cover a portion of the costs incurred for the CEO to attend and present at the Seoul International Congress on Endocrinology & Metabolism (SICEM) event.

ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS (AMEND)

YEAR ENDING 31st DECEMBER 2024

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

<i>Previous Year</i>	01/01/2023	Income	Expenditure	Transfer	31/12/2023
	£	£	£	£	£
Barnes Construction Golf Day	7,079	-	-	-	7,079
HRA Pharma - ACC films	5,000	-	-	-	5,000
Licence to use ACC film clips	800	-	-	-	800
Society for Endocrinology	1,591	-	(1,791)	200	-
Big Give - Counselling	-	1,369	(1,369)	-	-
National Lottery Community Fund - peer support	8,750	-	(4,596)	-	4,154
Elliot Dallon Charitable Trust	-	10,000	(10,000)	-	-
	23,220	11,369	(17,756)	200	17,033

17. Unrestricted Funds

	01/01/2024	Income	Expenditure	Transfer	31/12/2024
	£	£	£	£	£
General Fund	38,234	64,527	(71,913)	46,068	76,915
Designated Funds	69,769	12,000	(13,240)	(38,529)	30,000
	108,003	76,527	(85,153)	7,539	106,915

Description of funds

Unrestricted Fund

General:

These are funds available to the Charity for unrestricted use in the furtherance of its charitable aims and objectives. These funds may be revenue (income & expenditure) items or tied up in assets, e.g. Office/Computer Equipment.

Designated Funds (see Note 17.)

These funds outlined below have been designated by the Trustees for the purposes shown whereas, legally, they are unrestricted. For reporting purposes throughout these Financial Statements, they are therefore combined together as "Unrestricted".

<i>Previous Year</i>	01/01/2023	Income	Expenditure	Transfer	31/12/2023
	£	£	£	£	£
General Fund	49,093	69,299	(77,450)	(2,708)	38,234
Designated Funds	84,347	-	(17,086)	2,508	69,769
	133,440	69,299	(94,536)	(200)	108,003

ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS (AMEND)

YEAR ENDING 31st DECEMBER 2024

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

18. Designated Funds

	01/01/2024	Income	Expenditure	Transfer	31/12/2024
	£	£	£	£	£
Counselling Service	-	12,000	(13,240)	1,240	-
Research Fund	39,019	-	-	(39,019)	-
Hardship Fund	750	-	-	(750)	-
Personnel Contingency Fund	30,000	-	-	-	30,000
	69,769	12,000	(13,240)	1,240	69,769

Counselling Service £12,000 is designated annually to provide approximately 200 one-top-one sessions for our members with the psychological counsellor service provider, Rareminds

Research Fund Funds that were previously designated for research funding are insufficient for long-term use and have therefore been undesignated.

Hardship Fund AMEND's official Hardship Fund, previously available for small financial help grants to members, has been discontinued, and previously designated funds have therefore been released into general funds.

Personnel Contingency Fund These designated funds allow for the costs of redundancies in the event that the charity can no longer support paid staff, or that the charity is wound up.

<i>Previous Year</i>	01/01/2023	Income	Expenditure	Transfer	31/12/2023
Counselling Service	9,078	-	(11,586)	2,508	-
Research Fund	44,519	-	(5,500)	-	39,019
Hardship Fund	750	-	-	-	750
Personnel Contingency Fund	30,000	-	-	-	30,000
	84,347		(17,086)	2,508	69,769

19. Related Parties

There were no related party transactions in 2024 or 2023.

20. Trustee Remuneration

No trustee received any remuneration. One trustee received reimbursement of expenditure incurred for a DBS Check, amounting to £18 to meet the requirements for becoming a trustee. In 2023, one trustee received reimbursement of travel and subsistence expenses amounting to £518 to enable them to attend conferences, the AGM and trustee meetings.

ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS (AMEND)

YEAR ENDING 31st DECEMBER 2024

21. Reconciliation of Net Income/(Expenditure) to Net Cash Flow from Operating Activities

		2024	2023
	Note	£	£
Net income/(expenditure) for the reporting period (as in the Statement of Financial Activities)		(10,843)	(31,624)
Adjustments for:			
- Depreciation	11.	457	939
- (Increase) / decrease in debtors	12.	1,524	(3,630)
- (Increase) / decrease in stock		670	517
- (Decrease) / increase in creditors	14.	5,726	(1,762)
Net cash provided by / (used in) operating activities		(2,466)	(35,560)
Analysis of Cash and Cash Equivalents			
Cash in hand and in Bank	13.	113,263	115,729
		113,263	115,729

ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS (AMEND)

YEAR ENDING 31st DECEMBER 2024

22.

COMPARATIVE STATEMENT OF FINANCIAL ACTIVITIES

YEAR ENDED 31st DECEMBER 2023

	Unrestricted	Restricted	TOTAL
	£	£	£
Income			
Donations and gift aid	36,788	-	36,788
Charitable Activities	30,000	11,369	41,369
Investment Income	1,977	-	1,977
Other Income	534	-	534
Total Income	69,299	11,369	80,668
Expenditure			
Raising Funds	9,635	-	9,635
Charitable Activities	64,033	17,756	81,789
Support Costs	17,967	-	17,967
Governance Costs	2,901	-	2,901
Total Expenditure	94,536	17,756	112,292
Net income /(expenditure) for the year	(25,237)	(6,387)	(31,624)
Transfer between funds	(200)	200	-
Revaluation gains on investment assets		-	-
Net Movement in Funds	(25,437)	(6,187)	(31,624)
Reconciliation of Funds			
Total Funds brought forward	133,440	23,220	156,660
Total Funds carried forward	108,003	17,033	125,036